Healthcare and energy stocks both advanced 0.39% at midday Wednesday. The US Federal Reserve is expected to keep interest rates steady in its monetary policy statement on Wednesday.
Imugene (ASX:IMU) obtained fast-track designation from the US Food and Drug Administration for azer-cel, a potential treatment for relapsed or refractory diffuse large B-cell lymphoma. Azer-cel is in phase 1b clinical trial.
On the flip side, the utilities sector struggled, falling 0.95%. The S&P 500, Dow Jones, and Nasdaq composite indices fell in overnight trading and Australian stocks followed them lower.
Contact Energy (ASX:CEN, NZE:CEN) said its consent application for the proposed Southland Wind Farm project in New Zealand was denied by the Expert Consenting Panel convened under the COVID-19 Recovery Act of 2020.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。